NCT07284121 2026-02-27
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Hoffmann-La Roche
Recruiting
Clinical Trials
25 trialsNCT04158258 2026-02-12
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
Hoffmann-La Roche
Active not recruiting
NCT03782207 2026-01-08
IMreal
Hoffmann-La Roche
Active not recruiting
NCT04862949 2025-12-12
Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC
CHA University
Completed
NCT05287464 2025-11-26
International Multicentric Study ARON-1
Hospital of Macerata
Recruiting
NCT06117891 2025-11-12
REFINE-IO
Bayer
Recruiting
NCT05197504 2025-09-05
HCC
CHA University
Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT05713994 2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
NCT04920981 2024-11-07
CLINATEZO
Intergroupe Francophone de Cancerologie Thoracique
Completed
NCT05173298 2024-02-07
HCC
CHA University
Unknown
NCT06169904 2023-12-14
B7-Family Score in Urothelial Carcinoma
Shanghai Zhongshan Hospital
Completed
NCT05418660 2023-09-18
I-STOP
University of Milano Bicocca
Unknown
NCT03559647 2023-09-01
The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy
Hoffmann-La Roche
Completed
NCT03330886 2023-03-13
A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina
Hoffmann-La Roche
Completed
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT05609903 2022-11-08
Anastase
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Completed
NCT03790397 2022-06-03
OSIREX
Fundación GECP
Completed
NCT04465942 2021-08-23
Immunotherapy in Lung Cancer: Treatment After IO Cessation.
European Lung Cancer Working Party
Unknown
NCT04136470 2020-08-10
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics
Ardigen
Unknown
NCT04145232 2020-08-10
AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.
Ardigen
Unknown
NCT04115410 2020-05-28
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
Unknown
NCT04169867 2019-11-20
Polish Microbiome Map
Ardigen
Unknown
NCT03399643 2019-04-19
Announce
Hoffmann-La Roche
Terminated
NCT03228368 2017-07-24
The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients
First Affiliated Hospital of Zhejiang University
Unknown